207 related articles for article (PubMed ID: 24020822)
1. Nanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophages.
Zhang J; Nie S; Wang S
J Agric Food Chem; 2013 Sep; 61(38):9200-9. PubMed ID: 24020822
[TBL] [Abstract][Full Text] [Related]
2. Formulation, characteristics and antiatherogenic bioactivities of CD36-targeted epigallocatechin gallate (EGCG)-loaded nanoparticles.
Zhang J; Nie S; Martinez-Zaguilan R; Sennoune SR; Wang S
J Nutr Biochem; 2016 Apr; 30():14-23. PubMed ID: 27012617
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 Expression Through the 67-κDa Laminin Receptor and the TLR4/MAPK/NF-κB Signalling Pathway in Lipopolysaccharide-Induced Macrophages.
Li YF; Wang H; Fan Y; Shi HJ; Wang QM; Chen BR; Khurwolah MR; Long QQ; Wang SB; Wang ZM; Wang LS
Cell Physiol Biochem; 2017; 43(3):926-936. PubMed ID: 28957799
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin gallate decreases the micellar solubility of cholesterol via specific interaction with phosphatidylcholine.
Kobayashi M; Nishizawa M; Inoue N; Hosoya T; Yoshida M; Ukawa Y; Sagesaka YM; Doi T; Nakayama T; Kumazawa S; Ikeda I
J Agric Food Chem; 2014 Apr; 62(13):2881-90. PubMed ID: 24628603
[TBL] [Abstract][Full Text] [Related]
5. Anti-atherogenic effects of CD36-targeted epigallocatechin gallate-loaded nanoparticles.
Zhang J; Nie S; Zu Y; Abbasi M; Cao J; Li C; Wu D; Labib S; Brackee G; Shen CL; Wang S
J Control Release; 2019 Jun; 303():263-273. PubMed ID: 30999008
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative activity of tea catechins associated with casein micelles, using HT29 colon cancer cells.
Haratifar S; Meckling KA; Corredig M
J Dairy Sci; 2014 Feb; 97(2):672-8. PubMed ID: 24359816
[TBL] [Abstract][Full Text] [Related]
7. Preparation and antioxidant activity of green tea extract enriched in epigallocatechin (EGC) and epigallocatechin gallate (EGCG).
Hu J; Zhou D; Chen Y
J Agric Food Chem; 2009 Feb; 57(4):1349-53. PubMed ID: 19182914
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin gallate reduces human monocyte mobility and adhesion in vitro.
Melgarejo E; Medina MA; Sánchez-Jiménez F; Urdiales JL
Br J Pharmacol; 2009 Dec; 158(7):1705-12. PubMed ID: 19912233
[TBL] [Abstract][Full Text] [Related]
9. Reactive oxygen species scavenging activities and inhibition on DNA oxidative damage of dimeric compounds from the oxidation of (-)-epigallocatechin-3-O-gallate.
Qi X
Fitoterapia; 2010 Apr; 81(3):205-9. PubMed ID: 19751808
[TBL] [Abstract][Full Text] [Related]
10. Lipophilized epigallocatechin gallate (EGCG) derivatives as novel antioxidants.
Zhong Y; Shahidi F
J Agric Food Chem; 2011 Jun; 59(12):6526-33. PubMed ID: 21526762
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin-3-gallate Reduces Scavenger Receptor A Expression and Foam Cell Formation in Human Macrophages.
Chen SJ; Kao YH; Jing L; Chuang YP; Wu WL; Liu ST; Huang SM; Lai JH; Ho LJ; Tsai MC; Lin CS
J Agric Food Chem; 2017 Apr; 65(15):3141-3150. PubMed ID: 28367625
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin gallate improves serum lipid profile and erythrocyte and cardiac tissue antioxidant parameters in Wistar rats fed an atherogenic diet.
Ramesh E; Elanchezhian R; Sakthivel M; Jayakumar T; Senthil Kumar RS; Geraldine P; Thomas PA
Fundam Clin Pharmacol; 2008 Jun; 22(3):275-84. PubMed ID: 18485145
[TBL] [Abstract][Full Text] [Related]
13. Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy.
Nance CL; Siwak EB; Shearer WT
J Allergy Clin Immunol; 2009 Feb; 123(2):459-65. PubMed ID: 19203663
[TBL] [Abstract][Full Text] [Related]
14. Augmented cellular uptake of nanoparticles using tea catechins: effect of surface modification on nanoparticle-cell interaction.
Lu YC; Luo PC; Huang CW; Leu YL; Wang TH; Wei KC; Wang HE; Ma YH
Nanoscale; 2014 Sep; 6(17):10297-306. PubMed ID: 25069428
[TBL] [Abstract][Full Text] [Related]
15. Green tea polyphenol epigallocatechin-3-gallate increases atherosclerotic plaque stability in apolipoprotein E-deficient mice fed a high-fat diet.
Wang Q; Zhang J; Li Y; Shi H; Wang H; Chen B; Wang F; Wang Z; Yang Z; Wang L
Kardiol Pol; 2018; 76(8):1263-1270. PubMed ID: 29862488
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antiproliferative effect of epigallocatechin gallate when loaded into cationic solid lipid nanoparticles against different cell lines.
Silva AM; Martins-Gomes C; Fangueiro JF; Andreani T; Souto EB
Pharm Dev Technol; 2019 Dec; 24(10):1243-1249. PubMed ID: 31437118
[TBL] [Abstract][Full Text] [Related]
17. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization.
Jang JY; Lee JK; Jeon YK; Kim CW
BMC Cancer; 2013 Sep; 13():421. PubMed ID: 24044575
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling.
Hong MH; Kim MH; Chang HJ; Kim NH; Shin BA; Ahn BW; Jung YD
Life Sci; 2007 May; 80(21):1957-65. PubMed ID: 17379255
[TBL] [Abstract][Full Text] [Related]
19. Improving the effectiveness of (-)-epigallocatechin gallate (EGCG) against rabbit atherosclerosis by EGCG-loaded nanoparticles prepared from chitosan and polyaspartic acid.
Hong Z; Xu Y; Yin JF; Jin J; Jiang Y; Du Q
J Agric Food Chem; 2014 Dec; 62(52):12603-9. PubMed ID: 25483592
[TBL] [Abstract][Full Text] [Related]
20. Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation.
Frias I; Neves AR; Pinheiro M; Reis S
Drug Des Devel Ther; 2016; 10():3519-3528. PubMed ID: 27826184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
